Skip to content
TrialScanner

NCT01731951

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Phase 2CompletedGERNLead

Registry record

Lead sponsor
Geron Corporation
Conditions
Primary Myelofibrosis; Secondary Myelofibrosis; Myeloid Malignancies
Primary completion
May 24, 2018Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01731951 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT01731951: Imetelstat Sodium in... | TrialScanner